share_log

博安生物(06955.HK):阿柏西普眼内注射溶液(BA9101)在中国完成Ⅲ期临床试验及计划递交上市申请

Boan Biotech (06955.HK): Abbasip intraocular injection solution (BA9101) completed phase III clinical trials in China and plans to submit a marketing application

Gelonghui Finance ·  Apr 8 16:35

Boan Biotech (06955.HK) announced that the abibasip intraocular injection solution (“BA9101”) developed by the company has completed phase III clinical trials (clinical efficacy and safety comparison test) in China and plans to submit a marketing application.

Abbasip is a homologous dimeric glycoprotein formed by fusing the extracellular domain of human vascular endothelial growth factor receptor (VEGFR1Ig2 region and VEGFR2IG3 region) with the FC domain of human IgG1. It is a soluble inducing receptor that binds to VEGF-A, VEGF-B, and PlGF, and can inhibit the binding and activation of endogenous VEGF receptors with VEGF-A and PLGF, thereby treating pathological neovascularoid eye diseases of the retina and choroid.

Original Research Drug Alia(EYLEA) It was approved for marketing in the US and the European Union in 2011 and 2012, respectively. Currently approved indications include neovascularization (wet) age-related macular degeneration (NaMD), diabetic macular edema (DME), post-retinal vein occlusion (RVO), diabetic retinopathy (DR), myopic choroidal neovascularization (mCNV), and retinopathy (ROP) in premature infants. AaliyahIt was approved for marketing in China in 2018, and the indications are NAMD and DME.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment